Fig. 5From: A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancersAssociation of combined PD-L1 status and NLR at baseline (a), and 2–8 weeks after treatment start (b) with OSBack to article page